Teleflex Inc TFX

Morningstar Rating
$246.83 +1.88 (0.77%)
View Full Chart

Company Report

Teleflex Is Expanding Its Portfolio of Surgical and Interventional Devices

Over the past decade, Teleflex has transformed from a diverse industrial, commercial, and healthcare company to one focused on single-use medical devices for surgical and minimally invasive procedures. It has relied heavily on acquisitions and divestitures and is likely to remain acquisitive in future. It generally targets companies with revenue in the $50 million-$300 million range to expand its portfolio and footprint. The firm prioritizes the development and acquisition of relatively inexpensive devices—generally under $1,000—that are unlikely to be targeted by healthcare device intermediaries for cost-savings. As an example, one night's stay in a hospital can lead to billed expenses of over $10,000, with Teleflex’s products accounting for around $500, or 5% of the total hospital cost.

Price vs Fair Value

TFX is trading at a 423% premium.
Price
$246.83
Fair Value
$945.00
Uncertainty
Medium
1-Star Price
$643.58
5-Star Price
$976.80
Economic Moat
Bhsr
Capital Allocation
Hzqqt

Bulls Say, Bears Say

Bulls

UroLift provides a meaningful clinical benefit in an area of unmet needs. Together with Barrigel, Telelfex has a decent chance of building a strong business in interventional urology.

Bears

Historical acquisitions have not materially improved the company's return on capital, and the pricing and performance of future acquisitions should be carefully monitored.

News

Trading Information

Previous Close Price
$244.95
Day Range
$245.32249.91
52-Week Range
$177.63257.85
Bid/Ask
$242.02 / $251.60
Market Cap
$11.63 Bil
Volume/Avg
321,510 / 401,454

Key Statistics

Price/Earnings (Normalized)
18.07
Price/Sales
3.88
Dividend Yield (Trailing)
0.55%
Dividend Yield (Forward)
0.55%
Total Yield
0.55%

Company Profile

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Core
Total Number of Employees
14,500

Competitors

Valuation

Metric
TFX
COLO B
BDX
Price/Earnings (Normalized)
18.0739.5218.93
Price/Book Value
2.5511.982.70
Price/Sales
3.887.513.55
Price/Cash Flow
18.2857.5619.18
Price/Earnings
TFX
COLO B
BDX

Financial Strength

Metric
TFX
COLO B
BDX
Quick Ratio
1.230.531.20
Current Ratio
2.580.851.85
Interest Coverage
3.888.814.20
Quick Ratio
TFX
COLO B
BDX

Profitability

Metric
TFX
COLO B
BDX
Return on Assets (Normalized)
6.62%11.10%3.65%
Return on Equity (Normalized)
11.06%35.43%7.60%
Return on Invested Capital (Normalized)
8.92%15.15%5.30%
Return on Assets
TFX
COLO B
BDX

Medical Instruments & Supplies Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
NybnkpymKfl$170.3 Bil
Becton Dickinson & Co
BDX
KqjfdvvnKnxvnd$69.8 Bil
Alcon Inc
ALC
KcynxvbKrprbxr$49.3 Bil
ResMed Inc
RMD
QykhzqgzMfgkkvv$35.1 Bil
Coloplast AS ADR
CLPBY
TfjzvsjmlLrhgs$29.7 Bil
West Pharmaceutical Services Inc
WST
FpxwmxlnxYcgw$22.6 Bil
The Cooper Companies Inc
COO
GdwqmknShtllt$21.9 Bil
Baxter International Inc
BAX
NgmxnwhkFwfkhdm$19.9 Bil
Align Technology Inc
ALGN
PzfqhxgryJkslsn$19.0 Bil
Hologic Inc
HOLX
NdyhykrzXrdbvx$18.8 Bil

Sponsor Center